Dr.NOOPUR DAHAKE, N19436
BCVA for distance was recorded for diabetic patients both preinjection & one month post injection. Retinal OCT for central macular thickness (CMT) was performed on baseline & one month post injection. Patients having DME on OCT were subjected to 1.25 mg of Intravitreal Bevacizumab (Avastin) & changes in BCVA & macular thickness were compared using statistical analyses. Final BCVA analysis by subgroups demonstrated that 9 (16.93%) eyes remained stable, 47 (79.66%) eyes improved by 2 Snellens lines of BCVA & 3 (5.08%) eyes deteriorated by 2 snellens lines of BCVA. 59 eyes of 50 consecutive patients with a follow-up of 1 month & mean age of 60.5 years(8.45) were included in this analysis. The mean preinjection CMT was 424.38μm & mean CMT after 1 month of IVB injection was 331.33μm, with significant difference from the preinjection value (P<0.001). Thus, primary intravitreal bevacizumab at doses of 1.25mg seem to provide improvement in BCVA & OCT in DME after 1 months.
Leave a Comment